Skip to main content
. 2021 Oct 7;12:704172. doi: 10.3389/fimmu.2021.704172

Table 1.

Subject characteristics.

N Non-PGD PGD p-value
15 13
Recipient age, median [IQR]* 57.0 [26.8, 65.0] 60.5 [55.0, 63.5] 0.34
Male recipient, N (%) 6 (40) 9 (69) 0.24
Donor age, mean (SD) 33.7 (11) 43.6 (17) 0.08
Male donor, N (%) 11 (73) 10 (77) 1
Recipient BMI, mean (SD) 23.9 (5.0) 28.3 (3.6) 0.01
Donor BMI, mean (SD) 23.2 (4.1) 25.7 (3.3) 0.09
Recipient ethnicity, N (%) 0.21
 American Indian/Alaska Native 0 (0) 2 (15)
 Asian 2 (13) 3 (23)
 Black 2 (13) 0 (0)
 White 11 (73) 8 (62)
Donor ethnicity, N (%) 0.56
 American Indian/Alaska Native 1 (8) 3 (23)
 Asian 4 (31) 2 (15)
 Black 2 (15) 1 (8)
 White 6 (46) 7 (54)
Transplant indication category, N (%) 0.31
 A (obstructive) 1 (7) 1 (8)
 B (pulmonary vascular) 0 (0) 0 (0)
 C (cystic fibrosis) 4 (27) 1 (8)
 D (restrictive) 10 (67) 11 (85)
CMV status, N (%) 0.55
 Donor (−) Recipient (−) 2 (13) 2 (15)
 Donor (−) Recipient (+) 3 (20) 4 (31)
 Donor (+) Recipient (−) 6 (40) 2 (15)
 Donor (+) Recipient (+) 4 (27) 5 (39)
HLA mismatches, median [IQR]* 4 [4, 5] 4 [4, 6] 0.22
Double lung transplant, N (%) 15 (100) 13 (100) 1
Post-transplant days, median [IQR]* 370 [363, 371] 370 [369, 380] 0.24
Days of airway cell culture, median [IQR]* 14 [13, 19] 15 [14, 17] 0.28
Lung allocation score, median [IQR]* 49.3 [42.1, 62.8] 56.0 [44.6, 85.7] 0.52

BMI, body mass index in kg/m2; CMV, cytomegalovirus; HLA, human leukocyte antigen; IQR, interquartile range; N, number; PGD, severe primary graft dysfunction; SD, standard deviation

*Indicates a non-normal distribution was identified by Shapiro-Wilk test p-value of <0.05. These variables are reported as median with IQR and compared by Mann-Whitney U test.